{"doi":"10.1016/j.jval.2018.04.367","title":"Cost Effectiveness Of Direct Oral Anticoagulants (DOACS) Compared With Warfarin: A Literature Review","abstract":null,"journal":"Value in Health","year":2018,"id":685560,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1791108,"name":"SH, Chen","orcid":null,"position":1,"is_corresponding":false},{"id":1235121,"name":"Y Wang","orcid":"0000-0002-2929-2807","position":2,"is_corresponding":false},{"id":1791109,"name":"B Zhao","orcid":null,"position":3,"is_corresponding":false},{"id":1791107,"name":"Y Huang","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Cost Effectiveness Of Direct Oral Anticoagulants (DOACS) Compared With Warfarin: A Literature Review","abstract":null,"is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26207759","pmcid":null,"openalex_id":"https://openalex.org/W2811048362","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.11194553,"influential_citations":0,"citation_trend":[{"year":2024,"count":1}],"oa_status":"bronze","license":"http://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"http://www.valueinhealthjournal.com/article/S1098301518306673/pdf","host_type":"journal"},{"url":"http://www.valueinhealthjournal.com/article/S1098301518306673/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1098301518306673?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1098301518306673?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jval.2018.04.367","host_type":"journal"}],"fields_of_study":["Atrial Fibrillation Management and Outcomes","Health Systems, Economic Evaluations, Quality of Life"],"mesh_terms":[],"keywords":["Apixaban","Dabigatran","Rivaroxaban","Edoxaban","Medicine","Warfarin","Cost effectiveness","Intensive care medicine","Anticoagulant","Atrial fibrillation","Internal medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Decent work and economic growth"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-18T16:59:07.555015Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}